Prospects of nanotechnology and natural products for cancer and immunotherapy

• Jan Filipe Andrade Santos,
• Marcela Bernardes Brasileiro,
• Pamela Danielle Cavalcante Barreto,
• Ligiane Aranha Rocha and
• José Adão Carvalho Nascimento Júnior

Beilstein J. Nanotechnol. 2025, 16, 1644–1667, doi:10.3762/bjnano.16.116

• polyethylene glycol, optionally combined with chitosan or polyvinyl alcohol, and an anticancer agent such as cisplatin, doxorubicin, or temozolomide. The characterization of this technology involved

Radiosensitizing properties of dual-functionalized carbon nanostructures loaded with temozolomide

• Radmila Milenkovska,
• Nikola Geskovski,
• Dushko Shalabalija,
• Ljubica Mihailova,
• Petre Makreski,
• Dushko Lukarski,
• Igor Stojkovski,
• Maja Simonoska Crcarevska and
• Kristina Mladenovska

Beilstein J. Nanotechnol. 2025, 16, 229–251, doi:10.3762/bjnano.16.18

• , temozolomide (TMZ), a drug used for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM), was incorporated into multiwalled carbon nanotubes (MWCNTs) and a MWCNTs–graphene (MWCNTs-G) hybrid compound, covalently functionalized with polyethylene glycol (PEG) 6000 and folic acid (FA), with an

• nanostructures; cytotoxicity; glioblastoma multiforme; radiosensitizing properties; temozolomide; Introduction Carbon-based nanostructures (CNs) such as graphene and its derivatives, carbon nanotubes (CNTs), fullerenes, carbon quantum dots, carbon nanohorns and nanodiamonds (NDs), and their hybrids are becoming

• , and photodynamic therapy. Cytotoxic drugs acting by preventing DNA replication and apoptosis via methylation of guanine-rich areas in DNA and by cross-linking guanine and cytosine in DNA strains are a standard in chemotherapy. Among them, the prodrug temozolomide (TMZ) with its active metabolite 5-(3

Key for crossing the BBB with nanoparticles: the rational design

• Sonia M. Lombardo,
• Marc Schneider,
• Akif E. Türeli and
• Nazende Günday Türeli

Beilstein J. Nanotechnol. 2020, 11, 866–883, doi:10.3762/bjnano.11.72

• another study, arginine–glycine–aspartic acid peptide (RGD)-modified NLCs were used for the delivery of temozolomide (TMZ) and their efficacy was tested on a glioblastoma multiforme mouse model. The RGD-TMZ/NLCs displayed high antitumor efficacy in vivo, with an inhibition of the tumor four times higher